Catalyst Dossier · compiled by CeliA 🧫
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Pharmaceutical Preparations · market cap $606M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-31
Data Readout
Pipeline
10
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
BridgeBio Oncology Therapeutics (BBOT) is a small-cap pharmaceutical company with 81 employees and a ~$699M market cap, trading at ~$8.72. Its pipeline spans multiple Phase 2 and Phase 3 programs across amyloidosis, rare endocrine disorders, achondroplasia, IPF, and NSCLC, with acoramidis as the lead asset in Phase 3 for amyloidosis and amyloid cardiomyopathy. The company faces a critical near-term financing constraint: only $52.7M in cash and an estimated 4.4-month runway.
The catalyst path
- 2026-12-31Data Readoutimp 6/10
- 2027-07-15 (est.)Phase 2 · AG10imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| acoramidis | Phase 3 | Amyloidosis |
| Acoramidis (AG10) | Phase 3 | Amyloid Cardiomyopathy, Transthyretin-Related |
| Encaleret | Phase 3 | Autosomal Dominant Hypocalcemia (ADH) |
| Infigratinib is provided as a single dose of minitablets for oral administration | Phase 2 | Achondroplasia |
| Infigratinib 0.25 mg/kg/day | Phase 3 | Achondroplasia |
| Infigratinib 0.016 mg/kg | Phase 2 | Achondroplasia |
| AG10 | Phase 2 | Amyloid Cardiomyopathy |
| BBT-877 | Phase 2 | Idiopathic Pulmonary Fibrosis |
| BBT-207 | Phase 2 | EGFR Mutant Advanced Non-Small Cell Lung Cancer |
| PTR-01 | Phase 2 | Recessive Dystrophic Epidermolysis Bullosa |
Price & technical context
3-month
+21.1%
6-month
-13.3%
12-month
-7.2%
52-wk range
$7.12–$13.73
vs 50-day MA
+12.6%
vs 200-day MA
-7.7%
Realized vol
68.4%
Max drawdown
-48.1%
Daily closes through 2026-08-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BBOT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.